Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences, Inc. filed an 8‑K and supplemental proxy materials to correct a typographical error in its 2026 Annual Meeting proxy. The company confirms that Proposal 3 seeks approval for a reverse stock split in a range of 1‑for‑5 to 1‑for‑15, not 1‑for‑50.
The correction applies to the proxy card and notice of internet availability, while the proposal text already reflected the 1‑for‑15 maximum. The meeting remains scheduled for May 28, 2026 at 10:00 a.m. Eastern Time as a virtual event, and all other proposals and logistics are unchanged.
Enveric Biosciences is registering for resale up to 6,822,225 shares of its common stock. The registration covers (i) 98,000 issued shares and (ii) up to 6,724,225 shares issuable upon exercise of various warrants and pre-funded warrants from a April 16, 2026 private placement, including Placement Agent Warrants.
The filing states the company will not receive any proceeds from resales and that the registration satisfies registration rights granted in the Private Placement. The prospectus notes a reported Nasdaq closing price of $3.37 per share on April 21, 2026 and includes per-holder examples and Beneficial Ownership Limitations of 4.99% and 9.99%.
Enveric Biosciences, Inc. is registering the offer and resale of up to 6,822,225 shares of its common stock.
The registration covers resale by selling stockholders of (i) 98,000 shares issued in a private placement, (ii) 2,124,223 shares issuable upon exercise of pre-funded warrants, (iii) 2,222,223 shares issuable upon exercise of Series I Warrants, (iv) 2,222,223 shares issuable upon exercise of Series J Warrants, and (v) 155,556 shares issuable upon exercise of placement agent warrants. The company will receive no proceeds from resales; the selling holders may sell from time to time at prevailing market or negotiated prices. The registration relates to resale rights granted in connection with a Private Placement and includes customary beneficial ownership limits of 4.99% and 9.99% on warrant exercise; sales are subject to the plan of distribution described in the prospectus.
Enveric Biosciences, Inc. entered into a private placement financing with institutional investors, raising approximately $5.0 million in gross proceeds. The company agreed to sell 2,222,223 shares of common stock, or pre-funded warrants in lieu of shares, together with Series I and short-term Series J warrants, at a purchase price of $2.25 per share (or pre-funded warrant) and accompanying warrants.
The accompanying warrants have an exercise price of $2.00 per share and are exercisable immediately. Series I warrants will expire five years after the effective date of a resale registration statement, while Series J warrants will expire eighteen months after that date. If all Series I and Series J warrants are exercised for cash, Enveric could receive up to an additional $8.9 million in gross proceeds. The company plans to use net proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences, Inc. has called its 2026 annual stockholder meeting for May 28, 2026 at 10:00 a.m. Eastern Time, to be held exclusively online via live webcast. Stockholders of record as of March 30, 2026, when 1,887,535 shares of common stock were outstanding, may vote.
Investors are asked to elect six directors, cast an advisory “say‑on‑pay” vote on executive compensation, and extend prior approvals that give the board flexibility to effect a reverse stock split within a specified range and to increase authorized common shares from 100,000,000 to 5,000,000,000. The agenda also includes ratifying CBIZ CPAs P.C. as independent auditor for 2026 and approving potential adjournment to solicit additional proxies if needed.
The proxy details online and telephone voting procedures, broker voting rules, and how quorum and vote thresholds are calculated. It also outlines the company’s governance structure, board committees, cybersecurity oversight, and 2025 executive pay, including salary and stock‑based awards for the CEO, Chief Innovation Officer and CFO.
Enveric Biosciences, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held via webcast. The board asks stockholders to vote on electing six directors and on proposals that include an extension to effect a reverse stock split at ratios between 1-for-5 and 1-for-50 and an extension to increase authorized common stock from 100,000,000 to 5,000,000,000 shares. Other proposals include advisory approval of executive compensation, ratification of CBIZ CPAs P.C. as auditor, and an adjournment proposal.
Enveric Biosciences is a Delaware-based biotechnology company developing next‑generation, non‑hallucinogenic neuroplastogenic drugs for psychiatric and neurological disorders. Its lead candidate, EB‑003, a DMT‑derived compound from the EVM301 Series, is in preclinical development with IND‑enabling studies planned.
The company also maintains a large psychedelic‑inspired IP library (Psybrary™) and has out‑licensed certain cannabinoid and psychedelic assets. As of June 30, 2025, non‑affiliate equity value was about $3.6 million, and the auditor has raised substantial doubt about Enveric’s ability to continue as a going concern due to recurring losses and funding needs.
Enveric Biosciences reported a net loss attributable to stockholders of $4.0 million for the quarter ended December 31, 2025, compared with a net loss of $3.2 million a year earlier. Basic and diluted loss per share was $6.12 for the quarter. The company ended 2025 with $4.7 million in cash and raised gross proceeds of $12.2 million during the year through offerings, including $4.9 million in the fourth quarter.
Subsequently, Enveric raised about $1.5 million in a registered direct offering in January 2026 and approximately $1.45 million via an at-the-market offering in February 2026. Operationally, the company advanced its lead candidate EB-003, a non-hallucinogenic neuroplastogen, by completing pre-IND dose range finding studies, achieving key manufacturing milestones, and receiving FDA feedback allowing streamlined plans for an IND submission ahead of a planned first-in-human Phase 1 trial. Enveric also strengthened its intellectual property around the EVM301 and EVM401 compound series, executed licensing agreements for cannabinoid-COX-2 conjugates, expanded a topical cannabinoid collaboration, and completed a 1-for-12 reverse stock split while relocating its headquarters to Cambridge, Massachusetts.